查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557334

全球癌症疫苗市场 - 2024年至2029年预测

Global Cancer Vaccines Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球癌症疫苗市场预计将从2024年的101.96亿美元增加至2029年的175.17亿美元，预测期内年复合成长率为11.43%。

癌症疫苗用于治疗或预防癌症，分为预防性癌症疫苗和治疗性癌症疫苗。癌症疫苗是一种免疫疗法，可以帮助摧毁癌细胞、阻止肿瘤生长并防止未来癌症在体内发展。

由于不健康的生活习惯，全球癌症患者数量不断增加，是支持癌症疫苗市场成长的主要原因之一。越来越多的遗传性癌症研究和该领域的结论性结果预计将推动癌症疫苗市场的显着成长。 FDA 已核准针对人类乳突病毒 (HPV) 和乙型肝炎 (HBV) 的癌症疫苗，并可能在未来几年推动市场的显着成长。

众所周知，癌症疫苗会对身体造成严重的后遗症，这可能会抑制癌症疫苗市场的成长。越来越多的基于天然植物的阿育吠陀疗法用于癌症治疗的研究预计将为未来的市场成长带来一些障碍。老年人口中与老龄化相关的免疫力下降也可能威胁市场成长，因为它增加了疫苗接种后免疫反应减弱的可能性。此外，与癌症疫苗相关的高价格也可能阻碍市场成长。

全球癌症疫苗市场驱动因素：

  • 全球癌症患者数量的增加正在推动市场成长。

生活方式的改变、烟草和香烟等不健康产品的消费增加以及接触辐射和病毒正在增加全世界癌症患者的数量。根据世界卫生组织（WHO）预计，2022年将通报近2,000万新发癌症病例，死亡人数将达970万人。

肺癌是癌症死亡的主要原因，占新病例的 12.4%，其次是乳癌（11.6%）和大肠癌（9.6%）。到2050年，癌症新发病例数预计将达到5,500万例，比2022年增加77%。由于癌症死亡率不断上升，癌症疫苗的开发引起了高度关注。

  • 遗传性癌症症候群的增加：

有些癌症似乎是家族遗传，可能是由增加癌症风险的相同暴露引起的，例如吸烟或遗传性肥胖。然而，在某些情况下，例如遗传性癌症，异常基因会代代相传，导致癌症。据美国癌症协会称，所有癌症中约 5% 至 10% 是直接由突变引起的。预计该领域的更多研究和结论性成果将为未来几年癌症疫苗开发带来成长前景。

全球癌症疫苗市场的地域展望

  • 北美地区预计将大幅成长。

按地区划分，全球癌症疫苗市场分为北美、南美、欧洲、中东和非洲以及亚太地区。由于对癌症研究的持续投资和加强治疗过程的努力，预计北美将占据重要的市场占有率。

主要经济体，即美国，处于医疗创新的前沿，且癌症发生率正在显着增长。根据美国癌症协会预测，2023年美国新增癌症病例和死亡人数预计将分别达到1,950万人和609万人。

限制全球癌症疫苗市场的因素：

  • 免疫力较弱的老年人数量不断增加将阻碍市场成长。

癌症疫苗市场的主要限制因素之一是免疫力下降的老年人口不断增加。免疫力下降会抑制人体的免疫反应，进而降低癌症疫苗在体内有效反应的机会。根据联合国资料，到2050年，全世界大约六分之一的人将超过65岁。

  • 与癌症疫苗相关的副作用可能会限制市场扩张。

癌症治疗疫苗可能会引起多种副作用，这取决于多种因素，包括癌症类型、分期、疫苗治疗类型和剂量。美国国家癌症研究所列出了疲劳、头痛、呼吸困难、虚弱、发冷、发烧、低血压或高血压以及某些过敏反应等副作用。 Cyprecel-T 可导致人类中风。对此类副作用及其严重的恐惧可能会阻碍癌症疫苗市场的成长。

  • 其他治疗方案的可用性可能会对市场成长产生负面影响。

阿育吠陀和自然疗法在癌症治疗中的可用性可能会威胁癌症疫苗市场的成长。儘管没有严格的证据或核准明阿育吠陀作为一种医学系统可以治疗癌症，但研究人员发现瑜伽、冥想和阿育吠陀方法可作为癌症治疗的补充疗法。

此外，美国国家医学图书馆下属的国家生物技术研究中心编制了一份具有抗癌特性科学证据的特定植物清单，例如 Flacourtia Romanica、辣木、Ficus bengalensis 和 Semecarpus Anacardium。

全球癌症疫苗主要市场开拓：

  • 2024 年 5 月，英国国民医疗服务体系 (NHS England) 宣布，作为「癌症疫苗启动平台」的一部分，进行了首次针对治疗肠癌的个人化疫苗的患者试验。目的是让希望参加临床试验的癌症患者能够快速转运到最近的参与医院。
  • 2023 年 7 月，英国政府与 BioNtech SE 达成协议，到 2030 年为约 10,000 名癌症患者提供该生物技术公司正在开发的最新治疗方法和临床试验，包括疫苗试验。该协议确保患者能够从改进的治疗方法中受益。
  • 2022年12月，Moderna Inc.和默克公司将与默克公司的「KEYTRUDA」一起进行个人化mRNA癌症疫苗「mRNA-4157/V940」的2期试验，以治疗III/IV期黑色素瘤患者。治疗。

全球癌症疫苗市场区隔分析如下：

依技术

  • 树突状细胞 (DC) 癌症疫苗
  • 重组癌症疫苗
  • 抗原/佐剂癌症疫苗
  • 全细胞癌症疫苗
  • 病毒载体和 DNA 癌症疫苗
  • 其他的

按类型

  • 癌症预防疫苗
  • 治疗性癌症疫苗

按用途

  • 子宫颈癌
  • 摄护腺癌
  • 其他的

按用途

  • 儿科的
  • 成人

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 其他的
  • 中东/非洲
  • UAE
  • 南非
  • 以色列
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 台湾
  • 韩国
  • 其他的

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球癌症疫苗市场：依技术分类

  • 介绍
  • 树突状细胞 (DC) 癌症疫苗
  • 重组癌症疫苗
  • 抗原/佐剂癌症疫苗
  • 全细胞癌症疫苗
  • 病毒载体和 DNA 癌症疫苗
  • 其他的

第六章全球癌症疫苗市场：按类型

  • 介绍
  • 癌症预防疫苗
  • 治疗性癌症疫苗

第七章全球癌症疫苗市场：依应用分类

  • 介绍
  • 子宫颈癌
  • 摄护腺癌
  • 其他的

第八章全球癌症疫苗市场：依最终用户分类

  • 介绍
  • 小儿科
  • 成人

第九章区域癌症疫苗市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 其他的
  • 中东/非洲
    • 阿拉伯聯合大公国
    • 南非
    • 以色列
    • 沙乌地阿拉伯
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 台湾
    • 韩国
    • 其他的

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • AstraZeneca plc
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Moderna Inc.
  • OSE Therapeutics
  • Nouscom
  • OncBioMune Pharmaceuticals Inc.
  • Sanofi SA
  • Bristol-Myers Squibb
简介目录
Product Code: KSI061612163

The global cancer vaccine market is expected to grow at a compound annual growth rate of 11.43% over the forecast period, reaching US$17.517 billion in 2029 from US$10.196 billion in 2024.

Cancer vaccines are used to provide treatment or protection from cancer, which classifies them into prevention and treatment cancer vaccines. They are a type of immunotherapy that destroys cancer cells, stops the growth of tumors, and helps prevent any such cases in the body in the future.

The increased cases of cancer globally due to unhealthy living practices is one of the prime causes behind the cancer vaccine market's growth. The increasing research on inherited cancer and a definitive result in the field is expected to hold a large market for the growth of cancer vaccines. Cancer vaccines have been approved for Human papillomavirus (HPV) and Hepatitis B (HBV) by the FDA, which can provide significant growth to the market in the coming years.

Cancer vaccines are known for causing severe after-symptoms in the body, which may constrain the cancer vaccine market's growth. The increasing research for natural, plant-based Ayurveda therapy for cancer treatment is expected to create some hurdles for future market growth. The loss of immunity with age in the elderly population can also threaten the market's growth due to increased chances of low immune response after the vaccination. Besides that, the high price associated with cancer vaccines can also hamper their market growth.

Global Cancer Vaccine Market Drivers:

  • Increasing cases of cancer worldwide have propelled the market growth.

The change in lifestyle habits, followed by the increasing consumption of unhealthy products like tobacco and cigarettes and exposure to radiation and viruses, has been increasing the number of cancer patients worldwide. According to the World Health Organization , in 2022, nearly 20 million new cancer cases were reported, with an estimated number of deaths reaching up to 9.7 million.

Hence, the same sources further stated that lung cancer was the major cause of cancer deaths and accounted for 12.4% of new cases, followed by breast cancer at 11.6% and colorectal cancer at 9.6%. By 2050, the number of new cancer cases is estimated to reach 55 million, thereby witnessing a 77% increase over 2022's figure. The increasing rate of cancer mortality has put a major focus on the development of cancer vaccines.

  • Growing history of family cancer syndromes:

Certain types of cancer seem to run in families, which can be due to the same exposure that increases cancer risk like smoking and family running obesity. However, in some cases, like inherited cancer, an abnormal gene is passed along from one generation to another, which can lead to cancer. According to the American Cancer Society, around 5%-10% of all cancers result directly from mutations. Increasing research and a definitive result in this field are expected to hold growth prospects for developing cancer vaccines in the upcoming years.

Global Cancer Vaccine Market Geographical Outlook

  • North America is expected to grow significantly.

Regional-wise, the global cancer vaccine market is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is expected to account for a considerable market share owing to the ongoing investment in cancer research and efforts to bolster the treatment process.

Major economies, namely the USA, are at the forefront of medical innovations and are witnessing significant growth in cancer prevalence. According to the American Cancer Society, in 2023, the expected number of new cancer prevalence in the USA reached 19.5 million, with the number of deaths reaching up to 6.09 million.

Global Cancer Vaccine Market Restraints:

  • Increasing elderly population with low immunity will hamper the market growth.

One of the major restraints on the cancer vaccine market is the growing elderly population, which is accompanied by low-immunity in people. This is expected to serve as a constraint for the market's growth as a weak immune system hampers the immune response of the body and thus reduces the chances of an effective response by the cancer vaccines in the body. UN data suggests that by 2050, around 1 in 6 people in the world will be over the age of 65.

  • The side effects associated with cancer vaccines can restrain the market expansion.

Cancer Treatment Vaccines can cause various side effects, which depend on various factors like the type of cancer, how advanced it is, the type of vaccine treatment, the dosage, etc. The National Cancer Institute has listed side effects like fatigue, headache, trouble breathing, weakness, chills, fever, low and high blood pressure, and certain allergic reactions. Sipuleucel-T can trigger strokes in human bodies. Fear of such side effects and their severity may hamper the cancer vaccine market's growth.

  • The availability of other treatment options can negatively impact the market growth.

The availability of Ayurveda and natural therapies in cancer treatment could threaten the cancer vaccine market growth. Although there is no strict evidence or approval that Ayurveda as a system of medicine can treat cancer, researchers have found that yoga, meditation, and Ayurveda approaches are helpful as complementary therapies in cancer treatment.

Besides that, the National Center for Biotechnology Institution, which is part of the U.S. National Library of Medicine, has compiled a list of certain plants, such as Flacourtia romantic, Moringa oleifera, Ficus bengalensis, Semecarpus Anacardium, etc., that have scientific evidence of anticancer properties.

Global Cancer Vaccine Key Market Development:

  • In May 2024, NHS England announced the first patient trial with a personalized vaccine for treating bowel cancer, which formed part of its "Cancer Vaccine Launch Pad". This aimed to enable cancer patients willing to participate in clinical trials to be fast-tracked to the nearest participating hospital.
  • In July 2023, the UK government formed an agreement with BioNtech SE, which involved providing nearly 10,000 cancer patients with the latest therapies and clinical trials being developed by the biotech firms, including vaccine trials by 2030. The agreement would ensure that patients can benefit from more improved treatment options.
  • In December 2022, Moderna Inc. and Merck announced phase 2 of their "mRNA-4157/V940," a personalized mRNA cancer vaccine that would be tested along with Merck's "KEYTRUDA" to analyze the treatment of patients suffering from stage III/IV melanoma.

The Global Cancer Vaccine market is segmented and analyzed as follows:

By Technology

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Whole-Cell Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines
  • Others

By Type

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

By Application

  • Cervical Cancer
  • Prostate Cancer
  • Others

By End-Use

  • Pediatric
  • Adults

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Others
  • Middle East and Africa
  • UAE
  • South Africa
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Taiwan
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CANCER VACCINES MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Dendritic Cells (DC) Cancer Vaccines
  • 5.3. Recombinant Cancer Vaccines
  • 5.4. Antigen/Adjuvant Cancer Vaccines
  • 5.5. Whole-Cell Cancer Vaccines
  • 5.6. Viral Vector & DNA Cancer Vaccines
  • 5.7. Others

6. GLOBAL CANCER VACCINES MARKET BY TYPE

  • 6.1. Introduction
  • 6.2. Preventive Cancer Vaccines
  • 6.3. Therapeutic Cancer Vaccines

7. GLOBAL CANCER VACCINES MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cervical Cancer
  • 7.3. Prostate Cancer
  • 7.4. Others

8. GLOBAL CANCER VACCINES MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Pediatrics
  • 8.3. Adults

9. GLOBAL CANCER VACCINE MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. UK
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Others
  • 9.5. Middle East and Africa
    • 9.5.1. UAE
    • 9.5.2. South Africa
    • 9.5.3. Israel
    • 9.5.4. Saudi Arabia
    • 9.5.5. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. India
    • 9.6.4. Australia
    • 9.6.5. Taiwan
    • 9.6.6. South Korea
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. AstraZeneca plc
  • 11.2. GlaxoSmithKline plc.
  • 11.3. Merck & Co., Inc.
  • 11.4. Pfizer Inc.
  • 11.5. Moderna Inc.
  • 11.6. OSE Therapeutics
  • 11.7. Nouscom
  • 11.8. OncBioMune Pharmaceuticals Inc.
  • 11.9. Sanofi S.A.
  • 11.10. Bristol-Myers Squibb